![](https://cdn.sanity.io/images/0vv8moc6/mhe/8709b9286ceda5e0b38c4f031a89d996c98eeb43-946x532.png?fit=crop&auto=format)
Dr. Paul Frohna discusses the importance of non-pharmacological modalities, as well utilizing multidisciplinary care, for patients with idiopathic and progressive pulmonary fibrosis.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/8709b9286ceda5e0b38c4f031a89d996c98eeb43-946x532.png?fit=crop&auto=format)
Paul Noble, MD, discusses the evaluation process leading to patient diagnosis for IPF or PPF.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/d874f3a1ddfb2b8e343453ffce37f4937ea65296-1920x1080.png?fit=crop&auto=format)
A medical expert shares critical insights around biologic utilization.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/d874f3a1ddfb2b8e343453ffce37f4937ea65296-1920x1080.png?fit=crop&auto=format)
Jill Zouzoulas, MD, FACR, opens a discussion highlighting use of biologics in her practice.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/8709b9286ceda5e0b38c4f031a89d996c98eeb43-946x532.png?fit=crop&auto=format)
Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/8709b9286ceda5e0b38c4f031a89d996c98eeb43-946x532.png?fit=crop&auto=format)
Paul Noble, MD, opens a discussion surrounding the current treatment landscape and key elements to address in the management of idiopathic pulmonary fibrosis.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/cdc0a648c3841e1b61cc3fa40c338ab7ec28e364-1920x1080.png?fit=crop&auto=format)
Lawrence Eichenfield, MD, discusses promising avenues for future research and innovation in the field of atopic dermatitis.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/6b520c5fee0cad7fc2bec7c35602fc87436a5a56-1920x1080.png?fit=crop&auto=format)
A diabetes expert investigates the personal factors impacting patients' adoption of diabetes devices and technologies, while concurrently exploring specific plan policies, wellness initiatives, and benefit designs that could most effectively and equitably enhance diabetes outcomes across diverse demographic groups.
![](https://cdn.sanity.io/images/0vv8moc6/mhe/cdc0a648c3841e1b61cc3fa40c338ab7ec28e364-1920x1080.png?fit=crop&auto=format)
Focusing on the future treatment landscape of atopic dermatitis, Dr Eichenfield discusses current unmet needs and highlights standout studies and presentations from the 2024 AAD Annual Meeting.